Introduction {#S0001}
============

COPD is a heterogeneous disease characterized by progressive respiratory impairment and not fully reversible airway obstruction.[@CIT0001] Because COPD not only shows diverse clinical manifestations and prognosis, but also requires different treatments, multiple phenotypes are proposed to compliment this heterogeneity.[@CIT0002]--[@CIT0004] Along with the classical phenotypes of chronic bronchitis and emphysema,[@CIT0005] several additional variables related to the prognosis of COPD, including severity of airway limitation, demographics, radiographic findings, comorbidities and occurrence of acute exacerbation (AE) are proposed for categorization.[@CIT0002]--[@CIT0004],[@CIT0006]

Acute exacerbation of COPD (AE-COPD) is defined as deterioration of respiratory symptoms beyond normal day-to-day variations, resulting in changes of medication.[@CIT0007] An AE-COPD occurs on average about 0.34--3.00 times per person per year.[@CIT0008] Because AE-COPD is directly linked to high mortality and significant economic burden,[@CIT0009],[@CIT0010] its prediction is important. The most reliable predictor of AE-COPD is history of AE, and there is a specific patient population with intrinsic susceptibility to AE due to exposure to triggers.[@CIT0011] Patients who experience more than two moderate to severe AE incidents per year are called frequent exacerbators and have distinct characteristics including severely impaired FEV~1~, dyspnea score, and physiological score with worse outcomes.[@CIT0012] However, not much is known about the specific COPD subtype associated with AE occurrence based on the various clinical variables related to the occurrence of AE.

Cluster analysis is a method of data mining by defining data groups (clusters) based on measured characteristics to identify representation in specific groups.[@CIT0013] Because subtypes of COPD have commonly airflow limitations but different symptoms, demographics, and prognoses, cluster analysis is used to identify specific phenotypes.[@CIT0014] The aim of this study was to identify specific COPD subtypes through cluster analysis of variables known to be associated with COPD prognosis and to evaluate the usefulness of these subtypes to predict the first AE in COPD.

Materials and methods {#S0002}
=====================

Study population {#S0002-S2001}
----------------

Among the total 2,480 subjects registered in the Korea COPD Subgroup Study (KOCOSS) cohort recruited from 45 study centers between December 2011 and October 2014,[@CIT0015] 1,641 were initially screened for our study. We excluded 569 subjects that lacked airway limitation (measured FEV~1~/FVC ≥0.7), baseline pulmonary function test data, and follow-up data for the occurrence of AE ([Figure 1](#F0001){ref-type="fig"}). Finally, 1,195 subjects with seven clustering variables of age, body mass index (BMI), smoking status, history of asthma, COPD assessment test (CAT) score, post-bronchodilator (BD) FEV~1~% predicted, and diffusing capacity for carbon monoxide (DLco) % predicted were enrolled. We divided the subjects into four groups based on clustering analysis and named them according to the characteristics of the group as follows: asthma-COPD overlap (ACO), mild COPD, moderate COPD, and severe COPD. This study was approved by the Institutional Review Board of Ewha Womans University Hospital (ECT 2012--04-006--001) and all patients provided written informed consent before cohort entry.Figure 1Enrollment of patients.**Abbreviations:** BMI, body mass index; DLco, diffusing capacity of the lung for carbon monoxide; CAT, COPD assessment test.

Study design and outcomes {#S0002-S2002}
-------------------------

Data on demographics, lung function, 6MWD test, CAT score,[@CIT0016] COPD-specific version of St. George's Respiratory Questionnaire (SGRQ) score,[@CIT0017] laboratory findings, comorbidities, and medication were retrospectively reviewed from electronic medical records in the KOCOSS database. All medical data were obtained from case-report forms evaluated by physicians or trained nurses with 6-month interval patient examinations. Spirometry and 6MWD tests were performed according to standard American Thoracic Society guidelines with modification.[@CIT0018],[@CIT0019] The occurrence of AE, defined as respiratory deterioration requiring antibiotics or systemic corticosteroids with or without inhaler change, was also investigated at 6-month intervals by pulmonologists.

Statistical analysis {#S0002-S2003}
--------------------

Cluster analysis was performed using a K-means cluster analysis with the seven variables considered to contribute to specific COPD phenotypes.[@CIT0020] Clinical characteristics were compared according to the group after clustering. Continuous and categorical variables are expressed as mean±SD and number (percentage), respectively. One-way ANOVA or Kruskal--Wallis test was used for analyzing continuous variables. The Pearson chi-square test or Fisher's exact test wasused for analyzing categorical variables. The Kaplan--Meier method was used to express AE-free probability, and the differences between COPD groups were assessed using the log-rank test. The risk factors for AE including COPD subtypes were reported as HR with 95% confidence interval (CI) from the Cox's proportional-hazard model using time from cohort entry to first AE. Variables with a *p*-value \<0.1 from univariate analysis were candidates for multivariate analysis. A *p*-value \<0.05 (two-tailed) was regarded as statistically significant. All statistical analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).

Results {#S0003}
=======

Comparison of baseline demographics {#S0003-S2001}
-----------------------------------

Of a total of 1,195 subjects (mean age: 64.8 years, male: 92.5%), 196 (16.4%), 313 (26.2%), 345 (28.9%), and 341 (28.5%) were classified in the ACO, mild, moderate, and severe COPD groups, respectively, mostly based on the degree of airflow limitation. Among the four groups, the ACO group had the highest proportion of male patients (95.9% \[ACO\] vs 88.2% \[mild\] vs 94.2% \[moderate\] vs 93.2% \[severe\], *p*=0.004), the highest mean BMI (23.9 vs 23.7 vs 23.2 vs 21.8 kg/m^2^, *p*\<0.001), and the second oldest mean age (65.2 vs 67.7 vs 63.5 vs 63.5 years, *p*\<0.001), while pack-years of smoking in the ACO group was the lowest (38.4 vs 43.3 vs 43.3 vs 47.5 pack-years, *p*=0.001; [Table 1](#T0001){ref-type="table"}).Table 1Comparison of baseline characteristics according to the clustering groupsCharacteristicsACOMildModerateSevere*p*-valueNo196313345341Age, years65.2 (8.8)67.7 (7.9)63.5 (8.2)63.5 (8.7)\<0.001Male188 (95.9)276 (88.2)325 (94.2)313 (93.2)0.004BMI, kg/m^2^23.9±3.323.7±2.923.2±3.021.8±3.2\<0.001Smoking status0.852 Current49 (25.0)84 (26.8)93 (27.0)87 (25.5) Former126 (64.3)195 (62.3)214 (62.0)226 (66.3) Never21 (10.7)34 (10.9)38 (11.0)28 (8.2)Smoking amount, pyrs38.4±22.543.3±21.843.3±25.747.5±26.10.001Lung functions test FEV~1~, % predicted75.5±16.280.9±12.852.4±10.146.6±12.5\<0.001 FVC, % predicted91.2±16.795.5±13.882.1±17.178.8±18.0\<0.001 FEV~1~/FVC, %57.7±8.758.4±7.546.2±10.743.0±10.6\<0.001 DLco, % predicted110.5±16.971.6±12.381.0±9.749.8±11.4\<0.001 TLC, % predicted107.4±17.6104.0±21.5112.3±25.7109.5±25.9\<0.0016MWD, meters423.9±105.2405.2±107.8389.2±121.6364.7±104.8\<0.001Initial SpO~2~, %96.5±1.996.1±2.296.3±2.495.3±6.40.003Lowest SpO~2~, %95.6±2.694.7±3.494.5±4.192.2±8.2\<0.001CAT score12.2±6.813.7±8.115.6±7.717.5±8.1\<0.001SGRQ35.1±17.938.7±19.446.6±20.849.4±20.2\<0.001Laboratory findings WBC count, 10^3^/mm^3^7.2±2.47.3±1.97.8±2.47.9±2.80.001 Eosinophil, %3.0±2.53.4±2.83.4±3.73.3±3.90.059 CRP, mg/dL1.5±2.92.0±5.44.3±18.64.7±11.40.002 ESR, mm/h14.0±13.316.5±16.417.3±16.419.5±18.20.061[^1][^2]

In lung function comparison, the ACO group showed the best DLco (110.5 vs 71.6 vs 81.0 vs 49.8% predicted, *p*\<0.001) and 6MWD (423.9 vs 405.2 vs 389.2 vs 364.7 m, *p*\<0.001) values and the second-best values of FEV~1~ (75.5 vs 80.9 vs 52.4 vs 46.6% predicted, *p*\<0.001), FVC (91.2 vs 95.5 vs 82.1 vs 78.8% predicted, *p*\<0.001), and FEV~1~/FVC (57.7 vs 58.4 vs 46.2 vs 43.0, *p*\<0.001). Although the differences were very small, the ACO group also revealed the highest values of initial (96.5% vs 96.1% vs 96.3% vs 95.3%, *p*\<0.003) and lowest SpO~2~ levels (95.6% vs 94.7% vs 94.5% vs 92.2%, *p*\<0.001).

In laboratory findings, total white blood cell (WBC) count (7.2 vs 7.3 vs 7.8 vs 7.9 10^3^/mm^3^, *p*=0.001) and C-reactive protein (1.5 vs 5.4 vs 4.3 vs 4.7 mg/dL, *p*=0.002) levels were lowest in the ACO group among the four COPD subtypes.

Comorbidities and treatment status {#S0003-S2002}
----------------------------------

Among the four COPD groups, the ACO group showed the highest rate of gastroesophageal reflux disease (GERD, 16.3% \[ACO\] vs 9.0% \[mild\] vs 10.8% \[moderate\] vs 6.7% \[severe\], *p*=0.004) and the second highest rate of asthma (34.7% vs 27.2% vs 37.7% vs 34.3%, *p*=0.035; [Table 2](#T0002){ref-type="table"}). Hyperlipidemia (13.3% vs 17.0% vs 10.4% vs 9.3%, *p*=0.014), myocardial infarction (5.6% vs 7.1% vs 5.5% vs 2.3%, *p*=0.043), and atopic dermatitis (4.6% vs 4.8% vs 3.8% vs 2.9%) were the highest in the mild group, followed by the ACO group.Table 2Comparison of comorbidities according to the clustering groupsCharacteristicsACOMildModerateSevere*p*-valueNo196313345341Hypertension87 (44.4)124 (39.6)136 (39.4)126 (37.0)0.410Asthma68 (34.7)85 (27.2)130 (37.7)117 (34.3)0.035Diabetes mellitus38 (19.4)62 (19.9)59 (17.1)44 (12.9)0.083GERD32 (16.3)28 (9.0)37 (10.8)23 (6.7)0.004Allergic rhinitis29 (14.9)33 (10.6)35 (10.3)38 (11.4)0.393Hyperlipidemia26 (13.3)53 (17.0)35 (10.4)32 (9.3)0.014Myocardial infarction11 (5.6)22 (7.1)19 (5.5)8 (2.3)0.043Osteoporosis10 (5.1)17 (5.4)22 (6.4)11 (3.2)0.289Atopic dermatitis9 (4.6)15 (4.8)8 (2.4)1 (0.4)\<0.001Heart failure6 (3.1)8 (2.6)13 (3.8)10 (2.9)0.840Periperal vascular disease4 (2.0)5 (1.6)6 (1.7)5 (1.5)0.958Thyroid disease2 (1.0)10 (3.2)7 (2.1)11 (3.2)0.331IBD1 (0.5)3 (1.0)0 (0.0)5 (1.5)0.107[^3][^4]

Patients who were prescribed long-acting muscarinic antagonist (LAMA; 57.1% vs 58.8% vs 72.9% vs 77.3%, *p*\<0.001) or inhaled corticosteroid (ICS) plus long-acting beta2 agonist (LABA; 29.6% vs 21.1% vs 49.6% vs 46.1%, *p*\<0.001) were more frequent in the moderate and severe COPD groups compared to the ACO and mild COPD groups ([Table 3](#T0003){ref-type="table"}). The rates of theophylline (33.1% vs 27.8% vs 36.6% vs 33.1%, *p*=0.015) and roflumilast (0.6% vs 0.4% vs 5.9% vs 0.6%, *p*\<0.001) treatments were highest in the moderate COPD group and similar in the ACO and severe COPD groups.Table 3Comparison of treatment use according to the clustering groupsCharacteristicsACOMildModerateSevere*p*-valueNo196313345341LAMA97 (57.1)157 (58.8)229 (72.9)242 (77.3)\<0.001ICS plus LABA58 (29.6)66 (21.1)169 (49.6)159 (46.1)\<0.001Theophylline53 (33.1)68 (27.8)107 (36.6)53 (33.1)0.015Oral beta-2 agonist20 (12.4)14 (5.8)24 (8.3)20 (12.4)0.134Roflumilast1 (0.6)1 (0.4)17 (5.9)1 (0.6)\<0.001[^5][^6]

Occurrence of AE {#S0003-S2003}
----------------

The median follow-up period was 18 months (interquartile range: 6 to 36 months), and the ACO group had the longest follow-up duration ([Table 4](#T0004){ref-type="table"}). Total number of AEs was highest in the moderate COPD group (0.79 \[ACO\] vs 0.36 \[mild\] vs 0.90 \[moderate\] vs 0.86 \[severe\], *p*\<0.001\], while the mean annual frequency of AE (0.29 vs 0.18 vs 0.32 vs 0.39, *p*\<0.001) was highest in the severe COPD group. Of total patients, 424 (35.5%) experienced AE during the follow-up period. The median time for AE occurrence in the ACO group was 42 months (95% CI, 28.5--55.5 months), which was similar to that of the moderate COPD group (42.0 months; 95% CI, 28.3--55.7 months; [Figure 2](#F0002){ref-type="fig"}-[A](#F0002){ref-type="fig"}). The severe COPD group showed the shortest median time for AE (30.0 months; 95% CI, 23.5--36.5 months) among the four COPD groups.Table 4Number of acute exacerbation of COPD according to the clustering groupsCharacteristicsACOMildModerateSevere*p*-valueNo196313345341Follow-up duration, months24 (12--36)12 (6--24)18 (6--30)18 (12--36)\<0.001Total number of AE0.79±1.420.36±1.010.90±1.580.86±1.37\<0.001Number of AE per year0.29±0.490.18±0.510.32±0.490.39±0.58\<0.001[^7][^8] Figure 2Survival curve for acute exacerbation. (**A**) Kaplan--Meier curves showed the proportion of acute exacerbation free patients for four COPD subgroups. (**B**) Multivariate Cox survival curves showed the proportion of acute exacerbation free patients for four COPD subgroups.

Risk factors for AE {#S0003-S2004}
-------------------

In univariate analysis, COPD subtype, BMI, lung function test (FEV~1~, FVC, FEV~1~/FVC), lowest SpO~2~, CAT score, SGRQ, and total WBC count were significantly associated with the first AE occurrence ([Table 5](#T0005){ref-type="table"}). On multivariate analysis using non-clustered variables with a *p*-value \<0.1, COPD subtype, SGRQ (HR, 1.019; 95% CI, 1.014--1.024; *p*\<0.001), and GERD comorbidity (HR, 1.535; 95% CI, 1.116--2.112; *p*=0.008) were independent factors associated with the first AE. According to the multivariate Cox proportional hazard model, the HR for the first AE was significantly higher in the ACO (HR, 1.683; 95% CI 1.175--2.410; *p*=0.005), moderate (HR, 1.587; 95% CI, 1.145--2.200; *p*=0.006), and severe (HR, 1.664; 95% CI, 1.203--2.302; *p*=0.002) groups compared with the mild group ([Figure 2B](#F0002){ref-type="fig"}).Table 5Univariate and multivariate Cox analysis of risk factors associated with AE occurrenceCharacteristicsUnivariate analysisMultivariate analysisHR95% CI*p*-valueHR95% CI*p*-valueSubgroup Mild1.0001.000 ACO1.6051.146--2.2460.0061.6831.175--2.4100.005 Moderate1.9891.484--2.668\<0.0011.5871.145--2.2000.006 Severe1.6911.256--2.2770.0011.6641.203--2.3020.002Age, years0.9940.984--1.0040.217Male0.8810.666--1.1660.376BMI, kg/m^2^0.9760.952--1.0000.047Smoking status Current1.000 Former0.9780.812--1.1790.818 Never1.0340.782--1.3680.812Smoking amount, pyrs1.0020.999--1.0050.279FEV~1~, % predicted0.9840.980--0.988\<0.001FVC, % predicted0.9940.990--0.9980.0041.0010.995--1.0070.691FEV~1~/FVC, %0.9760.970--0.983\<0.001DLco, % predicted0.9990.995--1.0030.661TLC, % predicted1.0020.998--1.0050.3606MWD, meters0.9990.999--1.0000.0931.0000.999--1.0010.810Initial SpO~2~, %0.9970.968--1.0270.852Lowest SpO~2~, %0.9840.969--0.9990.0320.9910.968--1.0150.471CAT score1.0411.030--1.051\<0.001SGRQ1.0181.014--1.022\<0.0011.0191.014--1.024\<0.001Asthma0.9240.783--1.0890.345GERD1.2791.000--1.6370.0501.5351.116--2.1120.008WBC count, 10^3^/mm^3^1.0661.034--1.099\<0.0011.0310.987--1.0770.166CRP, mg/dL0.9970.983--1.0110.677ESR, mm/h1.0010.994--1.0080.871[^9]

Discussion {#S0004}
==========

Using age, BMI, smoking status, history of asthma, CAT score, FEV~1~, and DLco variables in clustering, we divided patients into the following four subtypes: ACO, mild, moderate, and severe COPD. The ACO group had the second-best FEV~1~ and FVC values and the highest BMI and DLco. The ACO group also showed the lowest CAT and SGRQ scores and higher rates of asthma and GERD as comorbidities. The COPD subtypes were an independent predictor for first occurrence of AE with SGRQ and GERD, and our ACO group showed a significant 76.6% increase in the rate of AE, with 65.9% and 69.6% increases in the moderate and severe groups, respectively, compared with the mild group.

Our study demonstrated that phenotype is linked to the occurrence of AE through clustering analysis using seven clinical variables without the history of AE. Previous studies identified the frequent exacerbator phenotype based on the history of AE, because a history of AE is the most powerful predictor of AE.[@CIT0011],[@CIT0012],[@CIT0021] The Exacerbations of COPD Patients (EXACO) study revealed the frequent exacerbator phenotype to have more impaired airflow limitation, respiratory symptoms, and daily activity limitations according to four-year follow-up of AE frequency.[@CIT0012] In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, frequent exacerbators also showed rapid decline in FEV~1~, the rate of GERD or heartburn symptoms, and elevated WBC counts compared with non-frequent exacerbators.[@CIT0011] However, the subtype related to the occurrence of AE based on clustering in our study showed mild airway limitation and respiratory symptoms and relatively high rates of asthma and GERD as comorbidities. These results suggest that, in addition to other factors known to be associated with AE, the ACO subtype of COPD seems to have a relationship with AE occurrence.

The reason we named one of the four clusters as a putative "ACO" group in this study is as follows. Diagnosis of ACO requires partial but not complete reversibility of airway limitation (post-BD FEV~1~\<80% predicted).[@CIT0022] Non-impairment of DLco with post-BD FEV~1~\<80% predicted in the putative ACO group could be evidence for non-existing emphysema. Among the four groups, the second-most common underlying diseases, asthma and atopic dermatitis, also supported the possibility of ACO.[@CIT0023] In clinical practice, the diagnosis of ACO, which indicates coexisting COPD and asthma, is challenging because the standard validated diagnostic criteria are still controversial.[@CIT0024] ACO patients are generally reported to have more frequent AE compared with pure COPD or asthma.[@CIT0025]--[@CIT0028] However, ACO patients in a previous study showed relatively severe airway limitation with impaired baseline post-BD FEV~1~, which is a strong risk factor for AE.[@CIT0011] In our study, the putative ACO subtype had moderate airway limitation but a high rate of AE-COPD. In addition, our ACO group showed different characteristics from the ACO groups as defined in other studies, showing a low level of inflammatory markers and modest airway limitation and preserved functional capacity.[@CIT0027]--[@CIT0029] In addition, better dyspnea scale score and functional parameters in the ACO group are also unique to our study compared with those in other studies. These results suggest that other factors are related to the occurrence of AE in addition to the conventional COPD severity indicators.

According to our study, the putative ACO group had the highest proportion of patients with GERD but lower proportions of patients who received LAMA and ICS plus LABA treatment due to mild airway limitation. The high AE occurrence rate in the ACO group might be attributed to the high presence of GERD despite relatively mild impairment of lung function. Several studies have reported that GERD is an independent risk factor for AE-COPD.[@CIT0011],[@CIT0030]--[@CIT0035] In the ECLIPSE study, AE-COPD was linked to the history of GERD or heartburn with prior history of AE.[@CIT0011] Meta-analysis based on five prospective and retrospective COPD studies also demonstrated that the risk of AE-COPD was significantly increased in patients with GERD (relative risk: 7.57; 95% CI, 3.57--14.94).[@CIT0030] Martinez et al demonstrated a significant relationship between the frequent exacerbator phenotype (≥2 COPD-AE per year) and GERD (odds ratio, 1.40; *p*=0.006).[@CIT0035] However, since most COPD patients with GERD rarely complain of either reflux symptoms (eg, heartburn, regurgitation) or respiratory symptoms (eg, cough, dyspnea),[@CIT0036] there is a possibility that GERD diagnosis often is overlooked. Silent aspiration of gastric contents due to GERD might lead to frequent AE-COPD by increasing bacterial burden in the respiratory tract.[@CIT0037] Sasaki et al showed that anti-reflux treatment significantly reduced the occurrence of AE in COPD patients without reflux symptoms,[@CIT0038] indicating that management of GERD could be beneficial for preventing AE-COPD.

Another reason for the high incidence of AE in our putative ACO group might be the low administration of ICS plus LABA, despite the relatively high proportion of asthma. Current Global Initiative for Asthma management guidelines recommend regular use of low-dose ICS as initial treatment for symptomatic asthma patients. Furthermore, if the predominance of asthma and COPD in ACO patients is difficult to determine, first-line treatment should include ICS, followed by addition of other inhalers if needed.[@CIT0039] In our study, ICS usage in the ACO group was low, which might be due to mild impairment of lung function, good exercise capacity, and low symptom score. While the ACO group in our study was an independent factor for first AE occurrence, the annual incidence of AE was highest in the severe group. Although we did not collect data on changes in medication during follow-up, these findings suggest that the ACO group might have experienced inhibition of further development of AE by appropriate treatment such as ICS after occurrence of the first AE event.

The limitations of our study are as follows. First, AE in our study was not based on strict criteria since this was a retrospective cohort study. The accurate time, severity, and clinical course of AE were not evaluated. However, the occurrence of AE was carefully assessed by experienced pulmonologists, and all patients were evaluated at 6-month intervals. Second, the relatively short follow-up duration might result in underestimated AE occurrence; however, since the annual exacerbation frequency ranged from two to three times per year depending on the severity of COPD,[@CIT0040] the median 18-month follow-up duration might be sufficient to assess the first development of AE. Lastly, subjects excluded due to insufficient follow-up data (n=470) might have led to selection bias. It was not possible to assume the cause of follow-up loss, but it might be another reason for underestimation of AE development.

Conclusion {#S0005}
==========

In conclusion, we identified the COPD subtypes susceptible to AE using cluster analysis with several clinical factors, including lung function. The ACO group had frequent AE-COPD despite good pulmonary function and exercise capacity and low dyspnea scale, which might be associated with GERD. Thus, subtypes susceptible to AE need more aggressive treatment strategies considering their comorbidities. Further studies should highlight the specific phenotype related to mortality or lung function decline in COPD patients.
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[^1]: **Note:**Data are presented as mean±SD or number (%).

[^2]: **Abbreviations:** BMI, body mass index; pyrs, pack-years; ; DLco, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; SpO~2~, oxygen saturation; CAT, COPD assessment test; SGRQ, St George's Respiratory Questionnaire; WBC, white blood cell; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
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